Phase 2 N=11 Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Fatigue · Quality of Life
Primary: Fatigue Severity Scale (FSS) — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Effect of Auricular Vagal Nerve Electrical Stimulation on Post-Treatment Lyme Disease Syndrome
Post-Treatment Lyme Disease Syndrome
Primary: Horowitz Lyme-Multiple Systemic Infectious Disease Syndrome Questionnaire — 50.5; 44.8; 33.8; 25.6 score on a scale — p=0.07
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 3 N=121 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
Neuroborreliosis, Borrelia Burgdorferi
Primary: Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment — 6.4; 6.4 units on a scale
N/A N=15 Feasibility of Teleyoga for Treatment of Lyme Disease
Lyme Disease
Primary: Change of Pain Score From Baseline — 5.7; 4.8; 2.9; 4.6 score on a scale
Phase 4 N=155 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment
Q Fever · Fatigue Syndrome, Chronic · Coxiella Infection
Primary: Checklist Individual Strength (CIS) — 31.6; 40.8; 37.8 score on a scale
Phase 3 N=77 Homeopathic Treatment of Post-acute COVID-19 Syndrome
Post-acute Covid-19 Syndrome
Primary: Fatigue Assessment Scale (FAS) — 32.9; 31.4; 29.0; 27.4 score on a scale
Phase 4 N=544 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
Erythema Migrans · Post-Lyme Disease Symptoms
Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants
Phase 4 N=26 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
N/A N=88 Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy
Traumatic Brain Injury · Fatigue
Primary: Multidimensional Assessment of Fatigue (MAF) — 33.332; 30.531; 27.993; 24.937 score on a scale
N/A N=306 Duration of Antibiotic Treatment of Erythema Migrans
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
N/A N=52 Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
Chronic Fatigue Syndrome
Primary: Cardiopulmonary Exercise Test (CPET) - ATVO2rel — 16.0; 10.6 mL/kg/min
Phase 2 N=155 Paxlovid for Treatment of Long Covid
Post-acute Sequelae of SARS-CoV-2 Infection · Long COVID
Primary: Number of Participants With No, Mild, Moderate, or Severe Symptoms at Week 10 According to the Core Symptoms Severity Scale Score — 3; 4; 22; 17 Participants — p=0.903
Phase 2 N=63 A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection · COVID-19 · Long COVID
Primary: Daily Diary Pain NRS — -2.2; -2.0 units on a scale
Phase 2 N=47 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
PANS · PANDAS · Obsessive Compulsive Disorder (OCD)
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 29.49; 28.43; 20.53; 23.45 units on a scale
Phase 2 N=80 Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
N/A N=3,570 A School-Based Intervention to Reduce Lyme Disease
Lyme Disease
Primary: The Incidence of Lyme Disease Among Children and Families Living in an Endemic Area Using an Educational Intervention — 1; 1 Number of cases incident Lyme disease
Phase 2 N=298 A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Systemic Lupus Erythematosus
Primary: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) — 294; 291; 283; 260 Participants
N/A N=21 Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention
Long COVID
Primary: Change in Functional Improvement Post-COVID-19 Over Time — 8.4; 21.05; 4.55; 6.6 score on a scale — p=.06
N/A N=193 Cognitive-Behavior Therapy for Posttraumatic Headache
Post-traumatic Headache · PTSD
Primary: Headache-related Disability Scores on the Headache Impact Test 6 (HIT-6) — 66.1; 66.1; 65.2; 61.9 score on a scale — p=<0.001
Phase 3 N=61 The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Irritable Bowel Syndrome
Primary: Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period — -4; -13 score on a scale
Phase 2 N=40 Sumatriptan as Treatment for Post-traumatic Headache
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
N/A N=30 Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2
Postacute Sequelae of Sars-CoV-2 · Post-Acute COVID-19 Syndrome · Widespread Chronic Pain
Primary: Mean Change in Functional Interference From Pain From Baseline to 4 Weeks (Blinded Phase) — 0.454; 0.198 score on a scale
Phase 2 N=52 Treatment of Post-Traumatic Brain Injury (TBI) Depression
Depression
Primary: Depression at Baseline — 27.5; 25.2 units on a scale
Phase 4 N=37 Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale (CAPS) — 72.6; 65.4; 40.7; 49.0 units on a scale — p=.01
N/A N=17 Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Primary: Number of Participants With Treatment Success — 8 Participants
N/A N=22 Treatment and Recovery Monitoring of Post TBI Symptoms
Brain Injuries, Traumatic
Primary: Change From Baseline in RPQ Score at Post-treatment Sessions — -4.6; -3.4 units on a scale
Phase 2 N=30 IVIG (Gamunex-C) Treatment Study for POTS Subjects
Postural Tachycardia Syndrome
Primary: Change in Symptoms Measured by Change in COMPASS-31 Score (After Initial Treatment Phase) — -5.5; -10.6 score on a scale — p=0.629
N/A N=74 Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
N/A N=16 Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Primary Outcome Measure: Percentage of Subjects Improved Global Response Assessment Scale — 4; 3 Participants — p=0.317